Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) has appointed Bill Weber as Chief Strategy Officer, effective October 7, 2026, the company announced. Weber brings more than 20 years of experience in corporate strategy and technology commercialization, including a previous role as Director of New Growth Ventures in 3M Company's CTO organisation. The appointment comes as Illumisoft advances commercialisation of its germicidal UV and far-UVC platforms, signalling a sharpened focus on disciplined execution and strategic partnerships.
Key Points
- Illumisoft Lighting Corp. (TSXV: UVC / OTCQB: FUVCF) announced the CSO appointment on October 8, 2026
- Bill Weber, founder of StrategyScout and former 3M New Growth Ventures director, joins as Chief Strategy Officer effective October 7, 2026
- 500,000 stock options granted at $1.12 per share, vesting equally over 24 months, expiring three years from grant date, subject to TSX Venture Exchange approval
- Investors may be watching how Weber's mandate accelerates commercialisation of SaniLume™ and SaniLux 216 nm far-UVC technology
Weber's Background and Role at Illumisoft
Weber will collaborate with CEO Ehsan Agahi and the leadership team on corporate strategy, commercial priorities, strategic partnerships, and market development. His career includes founding StrategyScout and serving as Director of New Growth Ventures within 3M's CTO organisation, where he identified and developed technology-driven growth opportunities. Earlier, he served as General Counsel of publicly traded Cbeyond Communications, overseeing regulatory strategy and strategic transactions through the company's eventual sale. He holds a B.S. from the United States Naval Academy and a J.D. from the University of Georgia School of Law, and previously served as an officer in the United States Marine Corps.
Stock Options Granted in Connection With Appointment
Concurrent with the appointment, Illumisoft's board of directors approved a grant of 500,000 stock options at an exercise price of $1.12 per common share. The options vest in equal instalments over 24 months and expire three years from the date of grant. The release states the grant remains subject to approval by the TSX Venture Exchange. The company did not disclose the total estimated value of the options in the announcement.
SaniLume and SaniLux Platforms at the Centre of Commercialisation Strategy
Weber's mandate is directly linked to advancing two core technologies: SaniLume™, Illumisoft's upper-room germicidal UV platform, and SaniLux, its 216 nm far-UVC technology currently in development. The disclosure suggests the company views this leadership addition as a lever for translating its existing technology portfolio and commercial pipeline into durable competitive positioning across healthcare, transportation, hospitality, and other built environments. Investors may be watching for updates on partnership activity and commercial pipeline milestones as Weber's strategy work unfolds.
President Graham Ballachey Steps Down, Moves to Advisory Role
Separately, the company announced that Graham Ballachey has resigned as President and will continue supporting Illumisoft in an advisory capacity. The release states the company thanks Ballachey for his service and looks forward to his contributions as an advisor. No further details regarding the transition timeline or advisory terms were disclosed. The immediate share price impact was not clear from available public information.



Please wait processing your request...